Group One Trading’s Bicycle Therapeutics BCYC Stock Holding History

Group One Trading’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$102K	Buy	24,100 +20,100	+503%	+$92.1K	﹤0.01%	4831
2026 Q1	$18.6K	Buy	4,000 +3,500	+700%	+$20K	﹤0.01%	6014
2025 Q4	$3.54K	Sell	500 -100	-17%	-$737	﹤0.01%	7332
2025 Q3	$4.64K	Hold	600	–	–	﹤0.01%	7580
2025 Q2	$4.17K	Sell	600 -300	-33%	-$2.39K	﹤0.01%	7156
2025 Q1	$7.64K	Buy	900 +600	+200%	+$7.07K	﹤0.01%	6423
2024 Q4	$4.2K	Hold	300	–	–	﹤0.01%	6484
2024 Q3	$6.79K	Buy	+300	New	+$6.92K	﹤0.01%	5766
2024 Q2	–	Sell	-2,000	Closed	-$49.8K	–	6719
2024 Q1	$49.8K	Sell	2,000 -16,100	-89%	-$342K	﹤0.01%	4728
2023 Q4	$327K	Sell	18,100 -32,100	-64%	-$531K	﹤0.01%	3441
2023 Q3	$1.01M	Sell	50,200 -37,500	-43%	-$858K	﹤0.01%	2266
2023 Q2	$2.24M	Buy	87,700 +49,100	+127%	+$1.14M	0.01%	1604
2023 Q1	$821K	Hold	38,600	–	–	﹤0.01%	2304
2022 Q4	$1.14M	Buy	+38,600	New	+$1.04M	﹤0.01%	2295

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GSK plc London $602M AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Group One Trading's BCYC Position: Q2 2026 in Review

Group One Trading opened a new position in Bicycle Therapeutics (BCYC) in Q2 2026: 1,938 shares worth $8.22K. The stake represents ﹤0.01% of the portfolio and ranks #6518 among its holdings. This is a return to the name: Group One Trading previously reported a position in BCYC as recently as Q2 2025.

Group One Trading first reported a position in BCYC in Q4 2022 and has held it in 10 quarters since. The position peaked at $2.14M in Q2 2023. 103 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

Group One Trading held 1,938 shares of Bicycle Therapeutics worth $8.22K as of Q2 2026.
Bicycle Therapeutics was a new Group One Trading position in Q2 2026.
Bicycle Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #6518 holding.
Group One Trading first reported a position in Bicycle Therapeutics in Q4 2022 and has held it in 10 quarters since.
Group One Trading's Bicycle Therapeutics position peaked at $2.14M in Q2 2023.
103 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.